VEGFC and myocardial infarction: No significant differences in expression of any of these factors were observed between vehicle- and VEGF-C(C156S)–treated hearts on day 7 after MI (Supplemental Figure 4), suggesting that lymphangiogenesis driven by VEGF-C(C156S) treatment does not alter macrophage polarization or favor a specific M1 or M2 subtype, but instead serves to reduce the overall macrophage load in the injured heart.